Functional expression of human prostaglandin E2 receptor 4 (EP4) in E. coli and characterization of the binding property of EP4 with G\textsubscript{q} proteins

Nam Hyuk Kim\textsuperscript{a}, Key-Sun Kim\textsuperscript{b}, Sang Chul Shin\textsuperscript{c}, Eunice Eunkyeong Kim\textsuperscript{c}, Yeon Gyu Yu\textsuperscript{a,\textastern};

\textsuperscript{a} Department of Chemistry, Kookmin University, 77, Jeongneung-ro, Seongbuk-gu, Seoul, 02707, Republic of Korea
\textsuperscript{b} Convergence research Center for Diagnosis Treatment and Care System of Dementia, Korea Institute of Science and Technology, Republic of Korea
\textsuperscript{c} Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, 02790, Republic of Korea

\textbf{A B S T R A C T}

Human prostaglandin E2 receptor 4 (EP4) is one of the four subtypes of prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) receptors and belongs to the rhodopsin-type G protein-coupled receptor (GPCR) family. Particularly, EP4 is expressed in various cancer cells and is involved in cancer-cell proliferation by a G protein signaling cascade. To prepare an active form of EP4 for biochemical characterization and pharmaceutical application, this study designed a recombinant protein comprising human EP4 fused to the P9 protein (a major envelope protein of phi6 phage) and overexpressed the P9-EP4 fusion protein in the membrane fraction of E. coli. The solubilized P9-EP4 with sarcosyl (a strong anionic detergent) was purified by affinity chromatography. The purified protein was stabilized with amphiliphic polymers derived from poly-\gamma-glutamate. The polymer-stabilized P9-EP4 showed specific interaction with the alpha subunits of G\textsubscript{q}, and a high content of \alpha-helical structure by a circular dichroism spectroscopy. Furthermore, the polymer-stabilized P9-EP4 showed strong heat resistance compared with P9-EP4 in detergents. The functional preparation of EP4 and its stabilization with amphiliphic polymers could facilitate both the biochemical characterization and pharmacological applications targeting EP4.

1. Introduction

Prostaglandins have multiple roles in human physiological processes and are synthesized from membrane-derived arachidonic acid via the reactions of cyclooxygenases and prostanoid synthases [1,2]. The five major prostaglandins referred to as prostanooids are prostaglandin E2 (PGE2), PGF2, PGE2, and thromboxanes. PGE2 is synthesized from prostaglandin h2 (PGH2) by prostaglandin E synthases and regulates multiple physiological processes, including inflammation [3–5], reproduction [6], and tumorigenesis [7,8]. PGE2 activates four different prostanoid receptors (EP1, EP2, EP3, and EP4), which are in the superfamnily of G protein-coupled receptors (GPCR). These receptors originate from four distinct genes and are distributed in different tissue or cell types [9]. The EP1 receptor activates PLC and increases in intracellular Ca\textsuperscript{2+} levels via coupling to G\textsubscript{q} [10], while the EP2 receptor couples to G\textsubscript{i} proteins, increases cAMP levels [11] and activates PKA. The EP3 receptor exists as multiple alternative splice variants resulting in different forms at the C-terminal tail region; these forms can couple with various G proteins, including G\textsubscript{q}, G\textsubscript{i}, or G\textsubscript{13} [12].

The EP4 receptor is expressed in various tissue cells, including immune, cardiovascular, gastrointestinal, respiratory, and various cancer cells [13]. It couples with G\textsubscript{i} proteins and activates PKA, thereby increasing levels of intracellular cAMP. EP4 also couples with G\textsubscript{q} and activates PI3K and Akt [14]. Gene-knockout experiments confirmed that EP4 is involved in inflammatory and pain responses and suggest that EP4 is a promising drug target against chronic inflammatory diseases such as rheumatism [15]. The EP4 receptor is also implicated in the development of breast, prostate, and colon cancers [13]. The knock down or antagonist of EP4 mitigates the progression of various cancers; therefore, a few efficient EP4 antagonists have been tested for use in cancer treatment.

Recently, an EP4 crystal structure was reported by Yosuke Toyoda et al. [16]. A complex structure of Fab and the mutant form of EP4 (in which the intracellular loop has been deleted) was crystallized along with an antagonist. Using this structural information, the ligand binding site was estimated to be near the antagonist binding region that was surrounded by the 5th, 6th, and 7th transmembrane helical regions of EP4. Although, the crystal structure revealed detailed information about the antagonist binding site, structural information on the interaction site of EP4 with the G protein is limited. This is because the EP4 protein used...
for the structural analysis lacks the critical intracellular loop region that is involved in the G protein interaction. Hence, a purified active form of EP4 action with G proteins as well as chemical regulators. Furthermore, an EP4 is required for the biochemical analysis of EP4, including its interaction with anti-P9 antibodies. The P9-EP4 band is indicated by an arrow. The C-terminal deleted form of EP4 as a P9-fusion protein in E. coli instead of aggregated in the cytoplasmic fraction [19]. The P9 domain significantly enhances the expression level of the fused GPCRs in the membrane fraction of E. coli instead of aggregated in the cytoplasmatic fraction [19]. The P9-assisted expression system of GPCRs would facilitate the purification and biochemical characterization of GPCRs. This study prepared a C-terminal deleted form of EP4 as a P9-fusion protein in E. coli. The expressed P9-EP4 was successfully purified, and the purified proteins showed specific binding both with Gαi and Gαs. The binding kinetics of P9-EP4 with both antagonists and agonists were analyzed by the spectral change in tryptophan (Trp) fluorescence. These results could facilitate the biophysical analysis of EP4 and the development of anti-EP4 drugs.

2. Materials and methods

2.1. Materials

The cDNA of EP4 was obtained from OriGene (USA). PGE2, isopro-pyl-β-D-thiogalactoside (IPTG), phenylmethylsulfonylfuoride (PMSF), and sarcosyl were obtained from Sigma (USA). The polyclonal P9 antibody was prepared from mice using the P9 protein as an antigen (Ab Frontier, Korea). The agonist (L-902688) and antagonist (ONO-AE3-208) of EP4 were supplied by Cayman (USA), and restriction enzymes and the T4 DNA ligase were obtained from New England Biolabs (UK). DNA polymerase was purchased from Takara (Japan) and Bioneer (Korea), and oligonucleotide synthesis and DNA sequencing were performed by Bioneer and Cosmogenetech (Korea). HRP-conjugated anti-mouse IgG was obtained from Sigma (USA), and Ni-NTA resin was purchased from Qiagen (Germany). The Superdex200 10/300 GL column was obtained from GE Healthcare (USA). All other consumable reagents were reagent grade.

2.2. Construction of EP4 expression vector and expression screening

The cDNA fragment representing amino acid 1–354 of human EP4 was amplified by PCR reaction with forward primer (5′-TATTTTCAGTCTAGATGGAATTCGAAACCAA CTTCTCCATCTCCGC-3′) and reverse primer (5′-GTGATGTTGAAGCTTCGAATTC CATTGCCTG TAACTCAATGTC-3′) and ligated at the EcoRI site for the pP9 vector (Fig. 1A) [17]. The expression vector of P9-EP4 was transformed into four different E. coli strains; Rosetta(DE3), Rosetta(DE3)-pLysS, BL21(DE3)-pRARE, and BL21(DE3)-RIP. Freshly transformed cells were cultured in 5 ml of Luria-Bertani (LB) medium at 37 °C supplemented with 100 μg/ml ampicillin and 30 μg/ml chloramphenicol until the OD600 of the culture reached 0.5–0.6. The expression of P9-EP4 was induced by adding 1 mM IPTG for 2 h at 37 °C, or for 3 h at 25 °C. Cells were harvested by centrifugation at 10,000 g for 20 min, and the expression level of P9-EP4 was measured using western blotting with anti-P9 antibodies and the T4 DNA ligase were obtained from New England Biolabs (UK). DNA polymerase was purchased from Takara (Japan) and Bioneer (Korea), and oligonucleotide synthesis and DNA sequencing were performed by Bioneer and Cosmogenetech (Korea). HRP-conjugated anti-mouse IgG was obtained from Sigma (USA), and Ni-NTA resin was purchased from Qiagen (Germany). The Superdex200 10/300 GL column was obtained from GE Healthcare (USA). All other consumable reagents were reagent grade.
2.3. Expression and purification of P9-EP4

BL21(DE3)-RIP cells harboring pP9-EP4 were grown in 5 ml of LB medium containing 0.1 mg/ml of ampicillin and 0.03 mg/ml of chloramphenicol for 12 h at 37 °C. A 1 ml amount of the pre-culture was inoculated into 50 ml of YTNR (yeast extract 1%, bacto tryptone 2%, NaCl 2%) medium containing 0.1 mg/ml of ampicillin and 0.03 mg/ml of chloramphenicol. It was cultured at 37 °C until the OD_{600} nm reached values of 1.0. One-third of the culture was inoculated into 150 ml of YTNR medium containing 0.1 mg/ml of ampicillin and 0.03 mg/ml of chloramphenicol and was cultured at 37 °C until the OD_{600} nm reached values of 1.0–2.0. This culture was then inoculated into a fermenter (Marardo-PDA, CNS, Korea) containing 3 L of culture medium (K_{2}HPO_{4} 0.3%, KH_{2}PO_{4} 0.5%, yeast extract 2%, glucose 2%, MgSO_{4}7H_{2}O 0.1%). The cells were grown at 37 °C at pH 6.8 in the presence of ~30% dissolved oxygen. The pH of the culture in the fermenter was maintained at 6.8 by the addition of a small volume of feeding medium (yeast extract 27.4%, (NH_{4})_{2}SO_{4} 0.15%, glucose 21.1%, and MgSO_{4}7H_{2}O 0.1%). The expression of P9-EP4 was induced by the addition of 1 mM IPTG for 3 h at 25 °C when the OD_{600} nm of the culture was 70. The cells were harvested by centrifugation, and the pellets were stored at −80 °C.

The pellets (10 g) were resuspended in 50 ml of buffer A (20 mM HEPES, pH 7.4, 1 mM PMSF, EDTA-free protease inhibitor cocktail) (GenDEPOT, USA), and the cells were lysed using a microfluidizer (M – 110P, Microfluidics, USA). Cell debris was removed from the lysate by centrifugation at 15,000 g for 30 min, and the membrane fraction was recovered from the pellet fraction after centrifugation at 100,000 g for 1 h. The membrane fraction was resuspended with buffer B (20 mM HEPES pH 7.4, 1% sarkosyl, 10 mM β-mercaptoethanol, and 10% glycerol) and the membrane proteins were solubilized by gentle agitation for 1 h at 4 °C. After removing the insoluble materials by centrifugation at 15,000 g for 30 min, the supernatant was loaded onto a Ni-NTA column. After washing the column with 5 mM imidazole in the equilibration buffer, the bound proteins were eluted with 50 mM imidazole. The eluted protein fraction was incubated with amphiphilic polymer APG at 17 °C (mass ratio of P9-EP4/APG equal to 1:4) for 2 h at 4 °C and concentrated with a 10-kDa molecular weight cutoff Amicon Ultra (Millipore, USA) concentrator. The concentrated protein was further purified by size-exclusion chromatography (Superdex200 10/300 GL), which was then pre-equilibrated with buffer C (20 mM HEPES pH 7.4 and 10% glycerol). The purified protein was stored at −80 °C until it was required.

2.4. Measurement of the interaction between P9-EP4 and the alpha subunits of G proteins

The alpha subunits of G_{a1}, G_{a2}, G_{a13}, and G_{a15} were prepared as previously described [19]. G_{a13} was immobilized in a high-binding 96-well plate (Corning, USA) and incubated with 10 µg/ml of P9-EP4 in 10 mM sodium phosphate pH 7.4, and the spectra of P9-EP4 in APG (0.063 mg/ml) were recorded in 10 mM sodium phosphate pH 7.4, and the spectra of P9-EP4 in maltose neopentyl glycol/cholesteryl hemisuccinate (MNG/CHS) (0.1 mg/ml) were recorded in 10 mM sodium phosphate pH 7.4, 0.05% MNG, 0.005% CHS. The scanning range was adjusted to 260–190 nm. The spectra were corrected for buffer contributions and were converted to molar ellipticity using a calculated molecular weight of 54401.46 Da. The secondary structure contents of P9-EP4 were predicted using the K2D2 program [20]. The temperature-scanning spectra of P9-EP4 were measured from 10 °C to 100 °C in the 220 nm fixed wavelength.

P9-EP4 in APG, sarkosyl, or MNG/CHS were heated at 80 °C for 30 min; the binding affinity with G_{a1} was measured by enzyme-linked immunosorbent assay (ELISA) using the same method described in section 2.4.

2.5. Secondary structure analysis and thermostability test of P9-EP4

The circular dichroism (CD) spectra of P9-EP4 were measured in a 1 mm quartz cuvette using a J-715 (JASCO, Japan) spectrometer at 20 °C. The spectra of P9-EP4 in APG (0.063 mg/ml) were recorded in 10 mM sodium phosphate pH 7.4, and the spectra of P9-EP4 in maltose neopentyl glycol/cholesteryl hemisuccinate (MNG/CHS) (0.1 mg/ml) were measured from 10 °C to 100 °C in the 220 nm fixed wavelength.

2.6. Analysis of ligand-dependent Trp fluorescence of P9-EP4

The intrinsic fluorescence spectra were measured using a FluoroMate FS-2 (Scinco, Korea) fluorescence spectrometer in a 10 mm quartz cuvette. The excitation wavelength was set to 295 nm, and the emission section 2.4.

2.7. Analysis of antagonist binding by isothermal titration calorimetry (ITC)

ITC experiments were performed using ITC200 instrument (MicroCal Inc.) and the data were analyzed using the program ORIGIN 7.0. The concentration of EP4 protein in the cell were 13 µM, while the syringe contained 200 µM of ONO-AE3-208. The ITC buffer contained 20 mM HEPES pH 7.4, 100 mM NaCl, and up to 1% DMSO. Titrations were carried out at 25 °C, using 13 injections of 2.5 µl each, injected at 150 s intervals. The experimental raw data were corrected for dilution by subtracting the values for buffer alone, and then fit by a one-site binding model. Titrations were fitted using a nonlinear least-squares curve-fitting algorithm with three floating variables: stoichiometry, binding constant (K_{D}), and change of enthalpy of interaction.

3. Results and discussion

3.1. Expression and purification of EP4

The P9 expression system in E. coli has been successfully applied for the expression of several human GPCR, such as ET_{A}, LPA_{1}, and LPA_{2}, as well as a ligand-gated ion channel (5HT_{3A}) [17–19,21]. This P9 expression system was successfully applied for the expression of E. coli. The P9 sequence may act as both the leader and anchor sequence that locates the EP4 at the periplasmic membrane of E. coli. The optimum conditions for the expression of P9-EP4 were examined in the expression level of P9-EP4 in various E. coli expression strains using Western blot analysis. As shown in Fig. 1B, all the tested strains demonstrated similar levels of expression. The expression of P9-EP4 at 25 °C is slightly less than at 37 °C. However, the degradation products of P9-EP4 appeared when the induction temperature was 37 °C. Hence, the mass expression of P9-EP4 was performed using the BL21(DE3)-RIP strain, and the expression of P9-EP4 was induced for 3 h at 25 °C. Typically, ~370 g of wet weight cells was obtained from 3 L of the fermented cell culture, and about ~1 mg of P9-EP4 was expressed at the membrane fraction per 1 g (wet weight) of E. coli cells (Fig. 1C). This result indicated that the P9 protein assisted expression system of EP4 in E. coli is highly efficient and convenient. This expression system would provide an easy access of purified EP4 for biochemical or biophysical study compared to other expression system of GPCR utilizing mammalian or insect cells. The P9-EP4 in the membrane fraction was poorly solubilized with non-ionic mild detergents (data not shown). Instead, it was efficiently
solubilized with sarkosyl (a strong anionic detergent) and purified using an Ni-NTA affinity column (Fig. 1D). After NTA-affinity chromatography, the purified P9-EP4 was heterogeneously eluted by size-exclusion chromatography (Fig. 1E, dotted line). However, gel-filtration chromatography revealed a mono-dispersed peak (Fig. 1E, solid line) for P9-EP4 stabilized in APG.

3.2. Specific interaction of the purified EP4 with the alpha subunits of G proteins

The activation of EP4 transduced the activation of G proteins. It was shown that EP4 was coupled with Gs proteins and induced an increase of cAMP at the cellular level [22], suggesting physical interaction with EP4 and Gs. Conversely, EP4 was also coupled with Gi proteins [14], whose activation resulted in the opposite effects on the cellular concentration of cAMP. However, the relative coupling of EP4 to these G proteins has not yet been investigated. To examine the relative binding of EP4 to the Gi or Gs proteins, the kinetic parameter of the interaction between the purified P9-EP4 and the Gi or Gs proteins was measured and compared. Gs1, Gi1, Gi2, and Gi3 were prepared as previously described [19]. Amount of P9-EP4 bound to the immobilized Gi subunits was measured using anti-P9 antibodies. As presented in Fig. 2B and C, P9-EP4 showed substantial binding affinities against the alpha subunits of Gi proteins. It demonstrated the highest binding affinity (Kd = 50 nM) to Gi3, and slightly reduced affinities (Kd = 88 nM, 175 nM, and 214 nM) to Gi1, Gi2, and Gi3, respectively. These results agree with the previously reported coupling of EP4 to Gi and Gs proteins. Also, these Kd values of P9-EP4 to the alpha subunit of G-proteins is comparable to the affinities of purified GPCRs such as LPA1, LPA2 or endothelin receptors to the alpha subunits of G-proteins [17–19]. It should be noted that the dissociation constants of EP4 to Gi3 and Gs1 are similar, suggesting that the relative cellular concentration of Gi3 or Gi1 proteins may be the dominant factor that directs the increase or decrease of cAMP after the activation of EP4.

3.3. Conformation and stability of EP4

The ability of P9-EP4 to interact with Gi and Gs proteins suggests that the purified P9-EP4 are in a natively folded state. To examine the conformation of P9-EP4, the CD spectra of P9-EP4 solubilized with detergent (MNG/CHS or APG) were analyzed. Although P9-EP4 in MNG/CHS or APG showed different size distributions, their CD spectra were almost identical (Fig. 3A). The CD spectrum of P9-EP4 revealed spectra of typical α-helical proteins; the secondary structure content was estimated using the K2D2 program [20]. The helical content of P9-EP4 was predicted as 45% from the CD spectrum. The helical content of P9-EP4 estimated using the K2D2 program [20]. The helical content of P9-EP4 estimated using the K2D2 program [20]. The helical content of P9-EP4 estimated using the K2D2 program [20]. The helical content of P9-EP4 estimated using the K2D2 program [20]. The helical content of P9-EP4 estimated using the K2D2 program [20].

The method of temperature-dependent denaturation is frequently applied to measure protein stability, which is reflected by the melting temperature. To examine the stability of purified P9-EP4, the
temperature-dependent change of molar ellipticity at 220 nm was measured. As presented in Fig. 3B, the P9-EP4 in MNG/CHS revealed a transition at around 65–70 °C, indicating that the protein undergoes thermal denaturation in this temperature range. However, P9-EP4 stabilized in APG showed a slight increase in ellipticity up to 100 °C. Additionally, the P9-EP4 after treatment at 80 °C for 30 min showed comparable binding activity to the G\textsubscript{α}i\textsubscript{1} protein, indicating that APG effectively stabilizes P9-EP4. This superior stabilizing activity of APG on EP4 compared with conventional detergent (such as sarkosyl or MNG/CHS) (Fig. 3C) may result from a unique interaction between APG and EP4. APG has more than 20 alkyl chains that can interact with EP4; this multiple interaction may stabilize the APG:P9-EP4 complex even at high temperatures.

3.4. Measurement of intrinsic tryptophan fluorescence of EP4 depending on agonist and antagonist interaction

Various agonistic and antagonistic modulators against EP4 have been identified from cell-based assays and pursued for clinical application. To optimize these modulators, the elucidation of the interaction modes of these compounds with EP4 is required. The transmembrane helical regions of EP4 are assumed to comprise the binding pocket of PGE2. The Arg257 at the 7th transmembrane helix had been important for the binding to PGE2 [16]. However, the extracellular loops are assumed to contribute for the binding of PGE2 as exemplified by the complex structures of S1P\textsubscript{1} or LPA\textsubscript{1} with their lipidic ligands [23,24]. To investigate the agonist or antagonist effects on the conformation of EP4, the intrinsic Trp fluorescence of EP4 was examined both in the absence and the presence of agonists and antagonists. P9-EP4 has three Trp residues at the 2nd and 3rd extracellular loops, and one at the 7th transmembrane helical region. A conformational change in P9-EP4 induced by an agonist or an antagonist may alter the microenvironment of these residues and effect a change in the Trp fluorescence spectrum. In the presence of PGE2 and an agonist, the 330 nm peak is substantially quenched. In contrast, the peak is rather de-quenched in the presence of an antagonist (Fig. 4A). The quenching and dequenching of the Trp fluorescence of P9-EP4 in the presence of an agonist and an antagonist, respectively, indicates that the environment of some of these Trp residues are changed to the opposite direction after the agonist/antagonist interaction of P9-EP4. It is assumed that the quenching of Trp fluorescence by agonist interaction induced the Trp residue in the 2nd or 3rd extracellular loop regions, which became more exposed to bulk solvent and enhanced the quenching of the Trp residues; the process is reversed for antagonist interaction. The opposed effect of the agonist or antagonist on the Trp fluorescence of P9-EP4 and the specific interaction of P9-EP4 with G\textsubscript{α}g and G\textsubscript{α}s proteins indicates that P9-EP4 has native conformation, which can be exploited for the discovery of novel EP4 modulators. Fig. 4B proves that APG:P9-EP4 complex is native conformation by measuring binding affinity with ONO-AE3-208.

Author contributions

N.H.K. and Y.G.Y. designed the experiments, analyzed the data and wrote the manuscript. N.H.K., K.-S.K., S.C.S., and E.E.K. performed the experiments.
Acknowledgments

This research was also supported by the Bio & Medical Technology Development Program (NRF-2017M3A9F6029733) of the National Research Foundation (NRF) funded by the Ministry of Science and ICT. This work was also supported by the R&D Convergence Program of the National Research Council of Science & Technology of Republic of Korea (CAP-16-03-KRIBB)

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.bbrep.2020.100871.

References

[1] W.L. Smith, D.L. DeWitt, R.M. Garavito, Cyclooxygenases: structural, cellular, and molecular biology, Annu. Rev. Biochem. 69 (2000) 145–182.
[2] W.L. Smith, I.J. Marnett, D.L. DeWitt, Prostaglandin and thromboxane biosynthesis, Pharmacol. Ther. 49 (1991) 153–179.
[3] S. Hara, D. Kamei, Y. Sasaki, A. Tanemoto, Y. Nakatani, M. Murakami, Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models, Biochimie 92 (2010) 651–659.
[4] D.C. Montrose, M. Nakashima, R.C. Murphy, S. Zarini, J.P. McAleer, A.T. Vella, D.W. Rosenberg, The role of PGE2 in intestinal inflammation and tumorigenesis, Prostagl. Other Lipid Mediat. 116–117 (2015) 26–36.
[5] M. Murakami, H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, F. Kojima, T. Ikeda, M. Fueki, A. Ueno, S. Oh-ishi, Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2, J. Biol. Chem. 275 (2000) 32783–32792.
[6] D. Kamei, K. Yamakawa, Y. Takegoshi, M. Ikiami-Nakanishi, Y. Nakatani, S. Oh-ishi, H. Yano, Y. Asuma, N. Hirazawa, K. Ohuchi, Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1, J. Biol. Chem. 279 (2004) 33684–33695.
[7] D. Kamei, M. Murakami, Y. Nakatani, Y. Ishikawa, T. Ishii, I. Kudo, Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis, J. Biol. Chem. 278 (2003) 19396–19405.
[8] A.A. Chaudry, K. Wahle, S. McClinton, L. Moffat, Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors, Int. J. Canc. 57 (1994) 176–180.
[9] Y. Sugimoto, S. Narumiya, Prostaglandin E receptors, J. Biol. Chem. 282 (2007) 11613–11617.
[10] H. Katoh, A. Watabe, Y. Sugimoto, A. Ichikawa, M. Negishi, Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in CDNA-transfected Chinese hamster ovary cells, Biochim. Biophys. Acta 1244 (1995) 41–48.
[11] A. Honda, Y. Sugimoto, T. Namba, A. Watabe, A. Irie, M. Negishi, S. Narumiya, A. Ichikawa, Cloning and expression of a CDNA for mouse prostaglandin E receptor EP2 subtype, J. Biol. Chem. 268 (1993) 7759–7762.
[12] A. Schmidt, K.H. Thieraura, W.D. Schneunig, H. Dinter, Splice variants of the human EP3 receptor for prostaglandin E2, Eur. J. Biochem. 228 (1995) 23–30.
[13] V. Konya, G. Marsche, R. Schuligoi, A. Heinemann, E-type prostaglandin receptor 4 (EP4) in disease and therapy, Pharmacol. Ther. 138 (2013) 485–502.
[14] H. Fujino, J.W. Regan, EP4 prostaglandin receptor coupling to a pertussis toxin-sensitive inhibitory G protein, Mol. Pharmacol. 69 (2006) 5–10.
[15] J.M. McCoy, J.R. Wicks, L.P. Aduol, The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis, J. Clin. Invest. 110 (2002) 651–658.
[16] Y. Toyoda, K. Morimoto, R. Suno, S. Horita, K. Hirata, Y. Sekiguchi, S. Yasuda, M. Shirouhi, T. Shimizu, Y. Urushihata, Y. Kajiwara, T. Inazumi, Y. Hotta, H. Aida, T. Nakane, Y. Shimizu, T. Nakagita, K. Tsuge, S. Yoshida, T. Kuribara, T. Honoya, Y. Sugimoto, N. Nomura, M. Sato, T. Hirokawa, M. Kinoshita, T. Murata, K. Takayama, M. Yamamoto, S. Narumiya, S. Iwata, T. Kobayashi, Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface, Nat. Chem. Biol. 15 (2019) 18–26.
[17] S.G. Han, S.I. Baek, W.K. Lee, P. Sudakar, Y.G. Yu, Overexpression and functional stabilization of recombinant human lysophosphatidic acid receptor 1 using an amphiphatic polymer, Bull. Kor. Chem. Soc. 38 (2017) 63–69.
[18] K. Lee, Y. Jung, J.Y. Lee, W.-K. Lee, D. Lim, Y.K. Shin, Y.G. Yu, Purification and characterization of recombinant human endothelin receptor type A, Protein Expr. Purif. 84 (2012) 14–18.
[19] S.-G. Han, S.-I. Baek, T.J. Son, H. Lee, N.H. Kim, Y.G. Yu, Preparation of functional human lysophosphatidic acid receptor 2 using a P9* expression system and an amphiphatic polymer and investigation of its in vitro binding preference to G proteins, Biochem. Biophys. Res. Commun. 487 (2017) 103–108.
[20] C. Perez-Iratxeta, M.A. Andrade-Navarro, K2D2: estimation of protein secondary structure from circular dichroism spectra, BMC Struct. Biol. 8 (2008) 25.
[21] J.H. Na, J. Shin, Y. Jung, D. Lim, Y.K. Shin, Y.G. Yu, Bacterially expressed human serotonin receptor 3A is functionally reconstituted in proteoliposomes, Protein Expr. Purif. 88 (2013) 190–195.
[22] J.W. Regan, EP2 and EP4 prostaglandin receptor signaling, Life Sci. 74 (2003) 143–152.
[23] M.A. Hanson, C.B. Roth, E. Jo, M.T. Griffith, F.L. Scott, G. Reinhart, H. Desale, B. Clemons, S.M. Cahalan, S.C. Schuerer, M.G. Sanna, G.W. Han, P. Kuhn, H. Rosen, R.C. Stevens, Crystal structure of a lipid G protein–coupled receptor, Science 325 (2012) 851–855.
[24] J.E. Chrenick, C.B. Roth, M. Terakado, H. Kurata, R. Omi, Y. Kihara, D. Warshaviak, S. Nakade, G. Asmar-Rovira, M. Mileni, H. Mizuno, M.T. Griffith, C. Rodgers, G.W. Han, J. Velasquez, J. Chun, R.C. Stevens, M.A. Hanson, Crystal structure of antagonist bound human lysophosphatidic acid receptor 1, Cell 161 (2015) 1633–1643.